BioCentury
ARTICLE | Company News

Ambry Genetics, Myriad Genetics diagnostic news

March 17, 2014 7:00 AM UTC

The U.S. District Court for the District of Utah denied Myriad's motion for preliminary injunction against Ambry for Ambry's standalone breast cancer 1 early onset (BRCA1) and BRCA2 tests. In University of Utah Research Foundation et al. v. Ambry Genetics Corporation, the court ruled that Ambry has raised a "substantial question" regarding Myriad's primer and method claims and that Myriad was unable to establish that its claim is likely to succeed. ...